Validation of small molecule inhibitors of PARG

Many types of cancer are currently untreatable. In Canada alone, 78,000 cancer-related deaths are seen annually, and obviously, new therapies are needed. We have identified the protein PARG as a potent stimulator of cancer growth and a valid target for anti-cancer therapy. However, specific, cell permeable inhibitors of PARG have historically been difficult to generate. […]

Read More
Characterization of infarct-sparing mechanisms of Celastrol and related compounds

The ability to repair or regenerate damaged heart presents a major challenge in the treatment of cardiovascular diseases. Current treatments are unsuccessful to regenerate dead myocardium and fail to address the challenge caused by the early loss of cardiac cells. The use of a new drug to stimulate protection of the heart during an ongoing […]

Read More